Esperion Therapeutics

Update in progress

ESPR (NGM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Esperion Therapeutics is a biopharmaceutical company focused on lowering LDL-C in the United States. It markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid with ezetimibe), once-daily oral non-statin medicines for adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia who need additional LDL-C reduction. It also develops NILEMDO (ACL inhibitor) and NUSTENDI. Headquartered in Ann Arbor, Michigan, it collaborates with Daiichi Sankyo and Otsuka.

Company score

Sentiment: 0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.10; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNGM
LocationUnited States
CEOMr. Sheldon L. Koenig M.B.A.
Founded2008
Employees294
Websitewww.esperion.com

Identifiers

ISINUS29664W1053
FIGIBBG004KB3S72
LEI549300OFU56UKEWVUS92
CUSIP16934W106
CIK0001434868